/
AKTX
$7.64+$0.63 (+9.07%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$12.6M
2M shares
52-week range
$3.02 – $49.60
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Change$-1292.37
Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
www.akaritx.com- Employees
- 5
- IPO / List date
- Dec 7, 2012
- HQ
- TAMPA, FL
Held by traders on TradeandTell
No one on the platform currently holds AKTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AKTX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-31 | 1-for-40reverse |
| 2023-08-17 | 1-for-20reverse |
| 2015-09-17 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded AKTX yet.
